ECSP034503A - Peptidos selectivos ciclicos - Google Patents

Peptidos selectivos ciclicos

Info

Publication number
ECSP034503A
ECSP034503A EC2003004503A ECSP034503A ECSP034503A EC SP034503 A ECSP034503 A EC SP034503A EC 2003004503 A EC2003004503 A EC 2003004503A EC SP034503 A ECSP034503 A EC SP034503A EC SP034503 A ECSP034503 A EC SP034503A
Authority
EC
Ecuador
Prior art keywords
selective peptides
peptides
cycle selective
cycle
bridges
Prior art date
Application number
EC2003004503A
Other languages
English (en)
Inventor
Xin Jie Chu
Li Chen
Wai Hing Cheung
Waleed Danho
Joseph Swistok
Yao Wang
Alan Yagaloff
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034503A publication Critical patent/ECSP034503A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a péptidos ciclados mediante puentes disulfuro o puentes lactama, con actividad agonista para el receptor de la melanomiento-4 (MC4-R), de utilidad para el tratamiento de la obesidad.
EC2003004503A 2000-08-30 2003-03-06 Peptidos selectivos ciclicos ECSP034503A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22918400P 2000-08-30 2000-08-30

Publications (1)

Publication Number Publication Date
ECSP034503A true ECSP034503A (es) 2003-04-25

Family

ID=22860145

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004503A ECSP034503A (es) 2000-08-30 2003-03-06 Peptidos selectivos ciclicos

Country Status (35)

Country Link
US (1) US7045591B2 (es)
EP (1) EP1315750B1 (es)
JP (1) JP4217069B2 (es)
KR (1) KR100483300B1 (es)
CN (1) CN100491396C (es)
AR (2) AR030504A1 (es)
AT (1) ATE353918T1 (es)
AU (2) AU8402601A (es)
BR (1) BR0113637A (es)
CA (1) CA2420058C (es)
CY (1) CY1106562T1 (es)
CZ (1) CZ2003584A3 (es)
DE (1) DE60126624T2 (es)
DK (1) DK1315750T3 (es)
EC (1) ECSP034503A (es)
ES (1) ES2280393T3 (es)
HR (1) HRP20030126B1 (es)
HU (1) HUP0303078A3 (es)
IL (2) IL154575A0 (es)
JO (1) JO2454B1 (es)
MA (1) MA27681A1 (es)
MX (1) MXPA03001721A (es)
MY (1) MY137457A (es)
NO (1) NO20030916L (es)
NZ (1) NZ523989A (es)
PA (1) PA8527201A1 (es)
PE (1) PE20020483A1 (es)
PL (1) PL366630A1 (es)
PT (1) PT1315750E (es)
RU (1) RU2239642C1 (es)
SI (1) SI1315750T1 (es)
TW (1) TWI248941B (es)
WO (1) WO2002018437A2 (es)
YU (1) YU15603A (es)
ZA (1) ZA200301015B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006604A2 (en) * 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
WO2003013571A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
AU2004235872A1 (en) * 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
EA200600055A1 (ru) * 2003-06-19 2006-08-25 Эли Лилли Энд Компани Агонисты рецептора меланокортина 4 (мк4 ) и их применение
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
JP2007532471A (ja) 2003-09-30 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ 新規メラノコルチンレセプターアゴニスト
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
EP1732586A1 (en) * 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
MXPA06011521A (es) * 2004-04-08 2007-03-21 Astellas Pharma Inc Compuesto ws 727713.
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2006048452A2 (en) * 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in treating of obesity
CN101052648A (zh) * 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
WO2006048450A2 (en) * 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treating obesity
US20080306008A1 (en) * 2004-11-04 2008-12-11 Nova Nordisk A/S Peptides for Use in the Treatment of Obesity
CA2609951A1 (en) * 2005-05-31 2006-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusale M Backbone cyclized melanocortin stimulating hormone (.alpha.s) analogs
MX2007015819A (es) * 2005-06-13 2008-02-22 Nastech Pharm Co Suministro de derivados peptidicos a traves de la mucosa.
US20080015304A1 (en) 2006-07-13 2008-01-17 Klaus Hintzer Aqueous emulsion polymerization process for producing fluoropolymers
US20070015937A1 (en) * 2005-07-15 2007-01-18 3M Innovative Properties Company Process for recovery of fluorinated carboxylic acid surfactants from exhaust gas
GB2430437A (en) * 2005-09-27 2007-03-28 3M Innovative Properties Co Method of making a fluoropolymer
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
CN101573371A (zh) * 2006-12-29 2009-11-04 弗·哈夫曼-拉罗切有限公司 环肽类化合物的合成方法
EP2132143B1 (en) * 2007-02-16 2012-12-26 3M Innovative Properties Company System and process for the removal of fluorochemicals from water
US20080264864A1 (en) * 2007-04-27 2008-10-30 3M Innovative Properties Company PROCESS FOR REMOVING FLUORINATED EMULSIFIER FROM FLUOROPOLMER DISPERSIONS USING AN ANION-EXCHANGE RESIN AND A pH-DEPENDENT SURFACTANT AND FLUOROPOLYMER DISPERSIONS CONTAINING A pH-DEPENDENT SURFACTANT
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
WO2009011261A1 (ja) * 2007-07-19 2009-01-22 Tokuyama Corporation ヒダントイン環を有する化合物及びその製造方法
KR20120075500A (ko) 2008-03-27 2012-07-06 그뤼넨탈 게엠베하 치환된 4-아미노사이클로헥산 유도체
AU2009228637B2 (en) * 2008-03-27 2013-12-19 Grunenthal Gmbh (Hetero-)aryl cyclohexane derivatives
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
EP2300036B1 (en) 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
BRPI1009644B1 (pt) 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
JP6622690B2 (ja) 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
CN107001440A (zh) * 2014-09-26 2017-08-01 拜耳制药股份公司 稳定化的肾上腺髓质素衍生物及其用途
WO2018074999A1 (en) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
US10653743B2 (en) 2015-10-15 2020-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法
CN106496005B (zh) * 2016-10-20 2019-04-09 上海毕得医药科技有限公司 一种4-(4-氯苯基)环己酮的合成方法
US10745444B2 (en) * 2017-04-17 2020-08-18 National Tsing Hua University Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN118530294B (zh) * 2024-05-10 2025-02-14 浙江大学 一种芳基二胺固载连接子、其前体以及制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237456A1 (de) * 1992-11-06 1994-05-11 Merck Patent Gmbh Cyclopeptide
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5858972A (en) 1996-01-11 1999-01-12 La Jolla Cancer Research Foundation Antithrombotic agents and methods of use
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
HK1044954B (en) 1999-03-29 2008-11-21 The Procter & Gamble Company Melanocortin receptor ligands

Also Published As

Publication number Publication date
AU8402601A (en) 2002-03-13
ZA200301015B (en) 2004-05-05
DK1315750T3 (da) 2007-06-11
MXPA03001721A (es) 2003-05-27
CY1106562T1 (el) 2012-01-25
CN100491396C (zh) 2009-05-27
JP4217069B2 (ja) 2009-01-28
HUP0303078A3 (en) 2012-02-28
EP1315750A2 (en) 2003-06-04
PT1315750E (pt) 2007-05-31
TWI248941B (en) 2006-02-11
JO2454B1 (en) 2008-10-09
JP2004507558A (ja) 2004-03-11
AU2001284026B2 (en) 2007-03-01
MY137457A (en) 2009-01-30
HUP0303078A2 (hu) 2003-12-29
PA8527201A1 (es) 2002-04-25
KR100483300B1 (ko) 2005-04-15
CA2420058C (en) 2009-04-07
NZ523989A (en) 2004-08-27
ATE353918T1 (de) 2007-03-15
EP1315750B1 (en) 2007-02-14
KR20030061788A (ko) 2003-07-22
BR0113637A (pt) 2004-02-25
CZ2003584A3 (cs) 2003-08-13
AR061422A2 (es) 2008-08-27
NO20030916D0 (no) 2003-02-27
YU15603A (sh) 2006-05-25
HRP20030126B1 (en) 2009-01-31
PL366630A1 (en) 2005-02-07
WO2002018437A2 (en) 2002-03-07
HRP20030126A2 (en) 2005-10-31
PE20020483A1 (es) 2002-06-06
US20020143141A1 (en) 2002-10-03
CN1451017A (zh) 2003-10-22
MA27681A1 (fr) 2006-01-02
CA2420058A1 (en) 2002-03-07
DE60126624T2 (de) 2007-11-22
DE60126624D1 (de) 2007-03-29
NO20030916L (no) 2003-02-27
IL154575A0 (en) 2003-09-17
US7045591B2 (en) 2006-05-16
RU2239642C1 (ru) 2004-11-10
ES2280393T3 (es) 2007-09-16
AR030504A1 (es) 2003-08-20
IL154575A (en) 2008-12-29
SI1315750T1 (sl) 2007-06-30
WO2002018437A3 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
AR030504A1 (es) Peptidos ciclicos selectivos
DK2308855T3 (da) 2,4-Diaminopyrimidinderivater
GB0115862D0 (en) Compounds
CY1108602T1 (el) Μεθοδος καθαρισμου της fsh
DK1446394T3 (da) Hidtil ukendte 1,2,4-thiadiazolderivater som melanocortinreceptormodulatorer
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
NO20035245L (no) Grunnleggende Wi-Fi-arkitektur for 802.11-nettverk
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DK2208727T3 (da) Diarylethere som opioidreceptorantagonister
DK1444215T3 (da) 1,2,4-Thiadiazoliumderivater som melanocortinreceptormodulatorer
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
BR0312491B1 (pt) processo para a telomerizaÇço de olefinas nço-cÍclicas.
ATE399770T1 (de) Tachykininrezeptorantagonisten
PT1401841E (pt) Derivados substituidos de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno como medicamentos para o tratamento da dor
CY1107254T1 (el) Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων
ATE398630T1 (de) Zyklische conotoxin-peptide
DK1511764T3 (da) Peptider og peptidomimetika, som er egnede til hæmning af aktiviteten af prostaglandin f2alfa-receptor
BR0215627B1 (pt) suporte de componente e gerador de radioisótopos.
DK1753776T3 (da) Camptotheciner, som er konjugeret i 7-stillingen til cykliske peptider, som cytostatiske midler
EA200700659A1 (ru) Циклизация пептидов
UY26913A1 (es) Péptidos cíclicos selectivos
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
ES1051900Y (es) Util para el tensado de alambre.
BR0314031A (pt) Tratamento de rinite não-alérgica por inibidores seletivos de fosfodiesterase 4
ES1051376Y (es) Higienizador para cuellos de botellines.